SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT04225429

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma

A multicenter, open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US.

NCT04225429 Epithelioid Sarcoma
HPO:Sarcoma Soft tissue sarcoma

1 Interventions

Name: Tazemetostat

Description: 800mg/dose taken orally twice every day.
Type: Drug

There is one SNP


1 V617F

JAK2 V617F) observed in cytogenetic testing and DNA sequencing. --- V617F ---

HPO Nodes